November 26, 2017 | Pharma biotech company Perrigo has completed the sale of its Israeli-based active pharmaceutical ingredients (API) business to New York investment firm SK  Capital for $110 million last week. The deal was first announced in August. In the agreement, Perrigo API, now called Wavelength Pharmaceuticals, will continue to supply existing and commercial […]